Skip to main content
SpringerLink
Log in

Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder”

  • Letter to the Editor
  • Published:
CNS Drugs Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 04 November 2022

The Original Article was published on 27 July 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder. CNS Drugs. 2022;36:897–915.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Food and Drug Administration. Integrated Review: Viloxazine extended-release capsules. https://www.fda.gov/media/148484/download. Accessed 3 Oct 2022.

  3. Balasundaram MK, Singh A. Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication. Drugs Ther Perspect. 2022;38:77–83.

    Article  Google Scholar 

  4. Singh A, Balasundaram MK, Singh A. Viloxazine for attention-deficit hyperactivity disorder: a systematic review and meta-analysis of randomized clinical trials. J Cent Nerv Syst Dis. 2022;20(14):11795735221092522. https://doi.org/10.1177/11795735221092522.

    Article  Google Scholar 

  5. Bewick V, Cheek L, Ball J. Statistics review 10: further nonparametric methods. Crit Care. 2004;8(3):196.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

    Alok Singh & Mahesh Kumar Balasundaram

Authors
  1. Alok Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahesh Kumar Balasundaram
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alok Singh.

Ethics declarations

Funding

No funding was received for the publication of this letter.

Conflicts of interest

The authors have no conflicts of interest to declare.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Authors' contributions

Both authors read and scrutinized the published article, the letter was prepared by Mahesh Kumar Balasundaram and reviewed by Alok Singh. Both authors approved the letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, A., Balasundaram, M.K. Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder”. CNS Drugs 36, 1331–1332 (2022). https://doi.org/10.1007/s40263-022-00966-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-022-00966-6

Search

Navigation